Mauro Panteghini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2431934/publications.pdf

Version: 2024-02-01

320 papers	11,974 citations	25034 57 h-index	37204 96 g-index
325 all docs	325 docs citations	325 times ranked	9236 citing authors

#	Article	IF	Citations
1	Lipase elevation in serum of COVID-19 patients: frequency, extent of increase and clinical value. Clinical Chemistry and Laboratory Medicine, 2022, 60, 135-142.	2.3	4
2	<scp>Î³â€Glutamyltransferase</scp> reference intervals in detail. Liver International, 2022, 42, 718-718.	3.9	1
3	A step towards optimal efficiency of HbA_{1c} measurement as a first-line laboratory test: the TOP-HOLE (Towards OPtimal glycoHemOgLobin tEsting) project. Clinical Chemistry and Laboratory Medicine, 2022, 60, 441-450.	2.3	1
4	Laboratory Community Should Be More Proactive in Highlighting the Negative Impact of Analytical Non-Selectivity of Some Creatinine Assays. Clinical Chemistry, 2022, 68, 723-723.	3.2	2
5	An approach for determining allowable between reagent lot variation. Clinical Chemistry and Laboratory Medicine, 2022, 60, 681-688.	2.3	19
6	Biological variation of serum cholinesterase catalytic concentrations. Clinical Chemistry and Laboratory Medicine, 2022, 60, e177-e180.	2.3	2
7	Improving D-dimer testing appropriateness by controlling periodicity of retesting: prevention is better than cure. Clinical Chemistry and Laboratory Medicine, 2022, .	2.3	2
8	â€˜Penelope testâ€™: a practical instrument for checking appropriateness of laboratory tests. Clinical Chemistry and Laboratory Medicine, 2022, .	2.3	1
9	Reply to Westgard etÂal.: â€˜Keep your eyes wide â€¦ as the present now will later be pastâ€™*. Clinical Chemistry and Laboratory Medicine, 2022, 60, e202-e203.	2.3	5
10	The simple reproducibility of a measurement result does not equal its overall measurement uncertainty. Clinical Chemistry and Laboratory Medicine, 2022, 60, e221-e222.	2.3	8
11	Harmonization Status of Serum Ferritin Measurements and Implications for Use as Marker of Iron-Related Disorders. Clinical Chemistry, 2022, 68, 1202-1210.	3.2	11
12	Linking lactate dehydrogenase to the severity of COVID-19 cannot ignore the employed methodology. American Journal of Emergency Medicine, 2021, 45, 652-653.	1.6	2
13	Serum potassium concentrations in COVID-19. Clinica Chimica Acta, 2021, 512, 26-27.	1.1	8
14	Verification of Harmonization of Serum Total and Free Prostate-Specific Antigen (PSA) Measurements and Implications for Medical Decisions. Clinical Chemistry, 2021, 67, 543-553.	3.2	33
15	Serum Prostate-Specific Antigen Testing for Early Detection of Prostate Cancer: Managing the Gap between Clinical and Laboratory Practice. Clinical Chemistry, 2021, 67, 602-609.	3.2	29
16	Performance specifications for measurement uncertainty of common biochemical measurands according to Milan models. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1362-1368.	2.3	38
17	Automatic reflex addition of serum magnesium determination to samples with severe hypocalcemia is an effective tool to detect and treat hypomagnesemia. Clinical Biochemistry, 2021, 92, 89.	1.9	1
18	Use of Neurosoft expert system improves turnaround time in a laboratory section specialized in protein diagnostics: a two-year experience. Clinical Chemistry and Laboratory Medicine, 2021, 59, e367-e369.	2.3	3

#	Article	IF	Citations
19	Prognostic role of Krebs von den Lungen-6 (KL-6) measurement in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1400-1408.	2.3	17
20	Is pre-biopsy serum prostate specific antigen retesting always justified? A study of the influence of individual and analytical factors on decision making for biopsy referral. Clinica Chimica Acta, 2021, 516, 77-82.	1.1	3
21	Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction. Cancers, 2021, 13, 3381.	3.7	25
22	The new multidisciplinary paradigm for fatty liver disease should also include the laboratory medicine contribution. Liver International, 2021, 41, 1981-1982.	3.9	1
23	Impact of optimizing pre-analytical phase on the diagnosis of gestational diabetes and related outcomes. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1981-1987.	2.3	6
24	Prospective validation of an automatic reflex test for identifying spurious elevations of mean corpuscular haemoglobin concentration due to the presence of cold agglutinins. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 1-3.	1.2	3
25	Pancreatic lipase: why laboratory community does not take enough care of this clinically important test?. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1914-1920.	2.3	4
26	Novel Criteria for the Observe-Zone of the ESC 0/1h-hs-cTnT Algorithm. Circulation, 2021, 144, 773-787.	1.6	25
27	Letter to the Editor: Serum Albumin in COVIDâ€19: A Good Example in Which Analytical and Clinical Performance of a Laboratory Test Are Strictly Intertwined. Hepatology, 2021, 74, 2905-2907.	7.3	6
28	Impact of managing affected results in haemolysed samples of an infant-maternity hospital using an unconventional approach. Clinical Biochemistry, 2021, 95, 49-53.	1.9	1
29	Improving the laboratory result release process in the light of ISO 15189:2012 standard. Clinica Chimica Acta, 2021, 522, 167-173.	1.1	6
30	Anti-tumour necrosis factor Î± antibodies and circulating lymphocyte phenotypes in inflammatory bowel disease. International Immunopharmacology, 2021, 100, 108081.	3.8	0
31	Sources and clinical significance of aspartate aminotransferase increases in COVID-19. Clinica Chimica Acta, 2021, 522, 88-95.	1.1	12
32	Optimizing Available Tools for Achieving Result Standardization: Value Added by Joint Committee on Traceability in Laboratory Medicine (JCTLM). Clinical Chemistry, 2021, 67, 1590-1605.	3.2	14
33	The internal quality control in the traceability era. Clinical Chemistry and Laboratory Medicine, 2021, 59, 291-300.	2.3	45
34	Searching for a role of procalcitonin determination in COVID-19: a study on a selected cohort of hospitalized patients. Clinical Chemistry and Laboratory Medicine, 2021, 59, 433-440.	2.3	27
35	Improving measurement uncertainty of plasma electrolytes: a complex but not impossible task. Clinical Chemistry and Laboratory Medicine, 2021, 59, e129-e132.	2.3	9
36	Aspartate aminotransferase in COVIDâ€19: A probably overrated marker. Liver International, 2021, 41, 2809-2810.	3.9	4

#	Article	IF	Citations
37	Biological variation of two serum markers for preeclampsia prediction. Clinical Chemistry and Laboratory Medicine, 2020, 58, e27-e28.	2.3	1
38	Highly sensitive troponin T measurement after pneumatic tube transportation: The sample type can make the difference. Clinica Chimica Acta, 2020, 503, 231-232.	1.1	0
39	Daily monitoring of a control material with a concentration near the limit of detection improves the measurement accuracy of highly sensitive troponin assays. Clinical Chemistry and Laboratory Medicine, 2020, 58, e29-e31.	2.3	7
40	Validation and verification of examination procedures in medical laboratories: opinion of the EFLM Working Group Accreditation and ISO/CEN standards (WG-A/ISO) on dealing with ISO 15189:2012 demands for method verification and validation. Clinical Chemistry and Laboratory Medicine, 2020, 58, 361-367.	2.3	8
41	Definition of analytical quality specifications for serum total folate measurements using a simulation outcome-based model. Clinical Chemistry and Laboratory Medicine, 2020, 58, e66-e68.	2.3	9
42	Further improvement of the quality of tube transportation system is needed to prevent â€˜seasonalâ€™ pseudohyperkalaemia. Clinica Chimica Acta, 2020, 510, 644-646.	1.1	1
43	Measurement of Serum Neuron-Specific Enolase in Neuroblastoma: Is There a Clinical Role?. Clinical Chemistry, 2020, 66, 667-675.	3.2	22
44	IFCC Working Group Recommendations for Correction of Bias Caused by Noncommutability of a Certified Reference Material Used in the Calibration Hierarchy of an End-User Measurement Procedure. Clinical Chemistry, 2020, 66, 769-778.	3.2	21
45	Implementation of metrological traceability in laboratory medicine: where we are and what is missing. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1200-1204.	2.3	27
46	Laboratory-related issues in the measurement of cardiac troponins with highly sensitive assays. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1773-1783.	2.3	11
47	The utility of measurement uncertainty in medical laboratories. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1407-1413.	2.3	64
48	A Comprehensive Appraisal of Laboratory Biochemistry Tests as Major Predictors of COVID-19 Severity. Archives of Pathology and Laboratory Medicine, 2020, 144, 1457-1464.	2.5	61
49	Trueness evaluation and verification of inter-assay agreement of serum folate measuring systems. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1697-1705.	2.3	12
50	Traceability validation of six enzyme measurements on the Abbott Alinity c analytical system. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1250-1256.	2.3	14
51	Derivation of performance specifications for uncertainty of serum C-reactive protein measurement according to the Milan model 3 (state of the art). Clinical Chemistry and Laboratory Medicine, 2020, 58, e263-e265.	2.3	17
52	Hypoalbuminemia and elevated D-dimer in COVID-19 patients: a call for result harmonization. Clinical Chemistry and Laboratory Medicine, 2020, 58, e255-e256.	2.3	17
53	Lactate dehydrogenase: an old enzyme reborn as a COVID-19 marker (and not only). Clinical Chemistry and Laboratory Medicine, 2020, 58, 1979-1981.	2.3	15
54	Impact of total automation consolidating first-line laboratory tests on diagnostic blood loss. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1721-1729.	2.3	5

#	Article	IF	Citations
55	Clinical Governance Remains a Priority in Total Laboratory Automation Era. journal of applied laboratory medicine, The, 2019, 4, 130-132.	1.3	6
56	Analytical validation of a highly sensitive point-of-care system for cardiac troponin I determination. Clinical Chemistry and Laboratory Medicine, 2019, 58, 138-145.	2.3	13
57	Reflex Testing of Free Prostate-Specific Antigen as Effective Health Care Policy. Archives of Pathology and Laboratory Medicine, 2019, 143, 1045-1045.	2.5	3
58	Defining the plasma folate concentration for optimal neural tube defects prevention cannot ignore the impact of the employed methodology. American Journal of Clinical Nutrition, 2019, 110, 780-781.	4.7	5
59	Clinical Governance Should Be a Priority When Care Delivery Systems Are Disrupted. Archives of Pathology and Laboratory Medicine, 2019, 143, 1046-1046.	2.5	1
60	Folate and vitamin B12 assays after recalibration to the WHO International Standard 03/178: making the interpretation as simple as possible, but not simpler. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1112-1114.	2.3	8
61	Procalcitonin: Between evidence and critical issues. Clinica Chimica Acta, 2019, 496, 7-12.	1.1	43
62	Commutability of reference and control materials: an essential factor for assuring the quality of measurements in Laboratory Medicine. Clinical Chemistry and Laboratory Medicine, 2019, 57, 967-973.	2.3	41
63	Symptoms Predictive of Acute Myocardial Infarction in the Troponin Era: Analysis From the TRAPID-AMI Study. Critical Pathways in Cardiology, 2019, 18, 10-15.	0.5	7
64	Documenting metrological traceability as intended by ISO 15189:2012: A consensus statement about the practice of the implementation and auditing of this norm element. Clinical Chemistry and Laboratory Medicine, 2019, 57, 459-464.	2.3	11
65	Making new biomarkers a reality: the case of serum human epididymis protein 4. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1284-1294.	2.3	23
66	A study of biological and lifestyle factors, including within-subject variation, affecting concentrations of growth differentiation factor 15 in serum. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1035-1043.	2.3	13
67	Letter to the Editor: Establishing Reliable Pediatric Percentiles of Serum Liver Enzyme Concentrations Cannot Ignore the Employed Methodology. Hepatology, 2019, 69, 1361-1362.	7.3	1
68	Trueness Evaluation and Verification of Interassay Agreement of 11 Serum IgA Measuring Systems: Implications for Medical Decisions. Clinical Chemistry, 2019, 65, 473-483.	3.2	5
69	Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction. International Journal of Cardiology, 2019, 276, 261-267.	1.7	25
70	Suppressing all test results in grossly hemolyzed samples: is this approach appropriate in every case?. Clinical Chemistry and Laboratory Medicine, 2019, 57, e118-e120.	2.3	4
71	Serum Î±-fetoprotein in pediatric oncology: not a childrenâ€™s tale. Clinical Chemistry and Laboratory Medicine, 2019, 57, 783-797.	2.3	32
72	Reply to â€œAnalytical performance assessment of a novel cartridge-based blood gas analyzerâ€• Clinical Biochemistry, 2019, 63, 156-157.	1.9	1

#	Article	IF	Citations
73	Plasma midregional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1161-1168.	2.3	23
74	The role of external quality assessment in the verification of in vitro medical diagnostics in the traceability era. Clinical Biochemistry, 2018, 57, 23-28.	1.9	30
75	Measurement uncertainty: Friend or foe?. Clinical Biochemistry, 2018, 57, 3-6.	1.9	23
76	Random uncertainty of photometric determination of hemolysis index on the Abbott Architect c16000 platform. Clinical Biochemistry, 2018, 57, 62-64.	1.9	15
77	Foreword. Clinical Biochemistry, 2018, 57, 1-2.	1.9	0
78	IFCC Working Group Recommendations for Assessing Commutability Part 1: General Experimental Design. Clinical Chemistry, 2018, 64, 447-454.	3.2	96
79	IFCC Working Group Recommendations for Assessing Commutability Part 2: Using the Difference in Bias between a Reference Material and Clinical Samples. Clinical Chemistry, 2018, 64, 455-464.	3.2	85
80	IFCC Working Group Recommendations for Assessing Commutability Part 3: Using the Calibration Effectiveness of a Reference Material. Clinical Chemistry, 2018, 64, 465-474.	3.2	43
81	How Clinical Laboratories May Improve Their Performance: The â€œHigh-Sensitivityâ€•Troponin Paradigm. Clinical Chemistry, 2018, 64, 621-623.	3.2	13
82	Traceability of alkaline phosphatase measurement may also vary considerably using the same analytical system: the case of Abbott Architect. Clinical Chemistry and Laboratory Medicine, 2018, 56, e135-e137.	2.3	5
83	Defining permissible limits for the combined uncertainty budget in the implementation of metrological traceability. Clinical Biochemistry, 2018, 57, 7-11.	1.9	24
84	Offering Aspartate Aminotransferase as a Reflex Test: An Easy but Effective Way to Improve Appropriateness of Laboratory Requests. American Journal of Clinical Pathology, 2018, 149, 456-457.	0.7	4
85	Laboratory testing in the emergency department: an Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC) and Academy of Emergency Medicine and Care (AcEMC) consensus report. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1655-1659.	2.3	16
86	Human Chorionic Gonadotropin Assays for Testicular Tumors: Closing the Gap between Clinical and Laboratory Practice. Clinical Chemistry, 2018, 64, 270-278.	3.2	23
87	Different calibrator options may strongly influence the trueness of serum transferrin measured by Abbott Architect systems. Clinica Chimica Acta, 2018, 477, 119-120.	1.1	2
88	Reply to: Hyperuricemia does not seem to be an independent risk factor for coronary heart disease. Clinical Chemistry and Laboratory Medicine, 2018, 56, e63-e64.	2.3	2
89	Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis of myocardial infarction. European Heart Journal, 2018, 39, 3780-3794.	2.2	78
90	Implementation of an internal quality control programme for the photometric determination of icteric index. Journal of Clinical Pathology, 2018, 71, 851-852.	2.0	6

#	Article	IF	Citations
91	Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up. Clinical Biochemistry, 2018, 60, 84-90.	1.9	13
92	Novel generations of laboratory instruments should not worsen analytical quality: The case of GEM Premier 5000. Clinical Biochemistry, 2018, 58, 128-130.	1.9	4
93	The role of laboratory in ensuring appropriate test requests. Clinical Biochemistry, 2017, 50, 555-561.	1.9	39
94	Pre-analytical and analytical aspects affecting clinical reliability of plasma glucose results. Clinical Biochemistry, 2017, 50, 587-594.	1.9	26
95	Evaluation of long-term imprecision of automated complete blood cell count on the Sysmex XN-9000 system. Clinical Chemistry and Laboratory Medicine, 2017, 55, e219-e222.	2.3	10
96	Serial Sampling of High-Sensitivity Cardiac Troponin T May Not Be Required for Prediction of Acute Myocardial Infarction Diagnosis in Chest Pain Patients with Highly Abnormal Concentrations at Presentation. Clinical Chemistry, 2017, 63, 542-551.	3.2	33
97	Prognostic Utility of a Modified HEART Score in Chest Pain Patients in the Emergency Department. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	64
98	Tackling serum folate test in European countries within the health technology assessment paradigm: request appropriateness, assays and health outcomes. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1262-1275.	2.3	18
99	Improving clinical laboratory performance through quality indicators. Clinical Biochemistry, 2017, 50, 547-549.	1.9	2
100	American Liver Guidelines and Cutoffs for â€œNormalâ€•ALT: A Potential for Overdiagnosis. Clinical Chemistry, 2017, 63, 1196-1198.	3.2	25
101	High sensitivity cardiac troponin T in patients not having an acute coronary syndrome: results from the TRAPID-AMI study. Biomarkers, 2017, 22, 709-714.	1.9	9
102	Analytical performance specifications for external quality assessment â€“ definitions and descriptions. Clinical Chemistry and Laboratory Medicine, 2017, 55, 949-955.	2.3	46
103	Total laboratory automation: Do stat tests still matter?. Clinical Biochemistry, 2017, 50, 605-611.	1.9	55
104	Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. Clinical Biochemistry, 2017, 50, 599-604.	1.9	14
105	Fast track protocols using highly sensitive troponin assays for ruling out and ruling in non-ST elevation acute coronary syndrome. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1683-1689.	2.3	12
106	Strategies to define performance specifications in laboratory medicine: 3 years on from the Milan Strategic Conference. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1849-1856.	2.3	56
107	Defining a roadmap for harmonizing quality indicators in Laboratory Medicine: a consensus statement on behalf of the IFCC Working Group â€œLaboratory Error and Patient Safetyâ€•and EFLM Task and Finish Group â€œPerformance specifications for the extra-analytical phasesâ€• Clinical Chemistry and Laboratory Medicine, 2017, 55, 1478-1488.	2.3	75
108	Evaluation of the trueness of serum alkaline phosphatase measurement in a group of Italian laboratories. Clinical Chemistry and Laboratory Medicine, 2017, 55, e47-e50.	2.3	19

#	Article	IF	Citations
109	Progress and impact of enzyme measurement standardization. Clinical Chemistry and Laboratory Medicine, 2017, 55, 334-340.	2.3	37
110	Clinical impact of glycolysis inhibition on plasma glucose results requires caution. Annals of Clinical Biochemistry, 2017, 54, 302-303.	1.6	4
111	Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM Strategic Conference. Clinical Chemistry and Laboratory Medicine, 2017, 55, 189-194.	2.3	130
112	Laboratory testing in the emergency department: An Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC) and Academy of Emergency Medicine and Care (AcEMC) consensus report. Emergency Care Journal, 2017, 13, .	0.3	4
113	A Summary of Worldwide National Activities in Chronic Kidney Disease (CKD) Testing. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2017, 28, 302-314.	0.7	5
114	The Use of Very Low Concentrations of Highâ€sensitivity Troponin T to Rule Out Acute Myocardial Infarction Using a Single Blood Test. Academic Emergency Medicine, 2016, 23, 1004-1013.	1.8	64
115	Are blood ammonia concentrations dependent on Î³-glutamyl-transferase levels in plasma?. Journal of Clinical Pathology, 2016, 69, 551-552.	2.0	3
116	Verification of the harmonization of human epididymis protein 4 assays. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1635-1643.	2.3	25
117	Optimal collection tubes for plasma glucose determination: confusion reigns supreme. Clinical Chemistry and Laboratory Medicine, 2016, 54, e281-e283.	2.3	5
118	Reference intervals for the Kryptor second-generation chromogranin A assay. Clinical Chemistry and Laboratory Medicine, 2016, 54, e335-e337.	2.3	4
119	Cystatin C provides a better estimate of the effect of glomerular filtration rate on serum human epididymis protein 4 concentrations. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1629-1634.	2.3	7
120	Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Annals of Emergency Medicine, 2016, 68, 76-87.e4.	0.6	294
121	Total error vs. measurement uncertainty: the match continues. Clinical Chemistry and Laboratory Medicine, 2016, 54, 195-6.	2.3	23
122	Laboratory medicine in the new healthcare environment. Clinical Chemistry and Laboratory Medicine, 2016, 54, 523-33.	2.3	45
123	More on the accuracy of the Architect enzymatic assay for hemoglobin A1c and its traceability to the IFCC reference system. Clinical Chemistry and Laboratory Medicine, 2016, 54, e71-3.	2.3	7
124	Generation of data on within-subject biological variation in laboratory medicine: An update. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 313-325.	6.1	81
125	Diagnostic and prognostic implications using age- and gender-specific cut-offs for high-sensitivity cardiac troponin T â€" Sub-analysis from the TRAPID-AMI study. International Journal of Cardiology, 2016, 209, 26-33.	1.7	101
126	Frequency of Pancreatic Hyperamylasemia in Human Immunodeficiency Virusâ€"Positive Patients in the Highly Active Antiretroviral Therapy Era. American Journal of Clinical Pathology, 2016, 145, 128-133.	0.7	6

#	Article	IF	Citations
127	Heparinate but not serum tubes are susceptible to hemolysis by pneumatic tube transportation. Clinical Chemistry and Laboratory Medicine, 2016, 54, 785-9.	2.3	11
128	Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine, 2016, 54, 7-15.	2.3	138
129	Role and Responsibilities of Laboratory Medicine Specialists in the Verification of Metrological Traceability of in Vitro Medical Diagnostics / Uloga I Odgovornosti Specijalista Laboratorijske Medicine U Verifikaciji MetroloÅ¡ke Sledljivosti In Vitro Medicinske Dijagnostike. Journal of Medical Biochemistry, 2015, 34, 282-287.	1.7	27
130	Once upon a time: a tale of ISO 15189 accreditation. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1127-9.	2.3	21
131	Body mass index does not influence human epididymis protein 4 concentrations in serum. Clinica Chimica Acta, 2015, 446, 163-164.	1.1	10
132	Evaluation of standardization capability of current cardiac troponin I assays by a correlation study: results of an IFCC pilot project. Clinical Chemistry and Laboratory Medicine, 2015, 53, 677-90.	2.3	33
133	Performance criteria for combined uncertainty budget in the implementation of metrological traceability. Clinical Chemistry and Laboratory Medicine, 2015, 53, 905-12.	2.3	60
134	How to assess the quality of your analytical method?. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1707-18.	2.3	40
135	Troponin T measured with highly sensitive assay (hsTnT) on admission does not reflect infarct size in ST-elevation myocardial infarction patients receiving primary percutaneous coronary intervention. Clinical Chemistry and Laboratory Medicine, 2015, 53, e173-4.	2.3	1
136	Colour coding for blood collection tube closures â€“ a call for harmonisation. Clinical Chemistry and Laboratory Medicine, 2015, 53, 371-6.	2.3	22
137	Preanalytical quality improvement. In pursuit of harmony, on behalf of European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working group for Preanalytical Phase (WG-PRE). Clinical Chemistry and Laboratory Medicine, 2015, 53, 357-70.	2.3	110
138	Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry and Laboratory Medicine, 2015, 53, 833-5.	2.3	398
139	Laboratory medicine as the science that underpins medicine: the â€œhigh-sensitivityâ€•troponin paradigm. Clinical Chemistry and Laboratory Medicine, 2015, 53, 653-64.	2.3	15
140	A new robust statistical model for interpretation of differences in serial test results from an individual. Clinical Chemistry and Laboratory Medicine, 2015, 53, 815-22.	2.3	10
141	Tumor Marker Ordering: Do Not Lose Control: A Prospective Clinical Trial. American Journal of Clinical Pathology, 2015, 144, 649-658.	0.7	17
142	The calibrator value assignment protocol of the Abbott enzymatic creatinine assay is inadequate for ensuring suitable quality of serum measurements. Clinica Chimica Acta, 2015, 450, 125-126.	1.1	16
143	Human epididymis protein 4: Factors of variation. Clinica Chimica Acta, 2015, 438, 171-177.	1.1	46
144	Is serum human epididymis protein 4 ready for prime time?. Annals of Clinical Biochemistry, 2014, 51, 128-136.	1.6	16

#	Article	IF	Citations
145	Standardization and analytical goals for glycated hemoglobin measurement. Clinical Chemistry and Laboratory Medicine, 2014, 52, .	2.3	0
146	The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1625-31.	2.3	23
147	Better blood collection tubes for plasma glucose: ready for prime time?. Clinical Chemistry and Laboratory Medicine, 2014, 52, e87-9.	2.3	7
148	Verification of in vitro medical diagnostics (IVD) metrological traceability: Responsibilities and strategies. Clinica Chimica Acta, 2014, 432, 55-61.	1.1	72
149	Harmonization of automated hemolysis index assessment and use: Is it possible?. Clinica Chimica Acta, 2014, 432, 38-43.	1.1	90
150	Soluble transferrin receptor in complicated anemia. Clinica Chimica Acta, 2014, 431, 143-147.	1.1	38
151	Evaluation of the impact of standardization process on the quality of serum creatinine determination in Italian laboratories. Clinica Chimica Acta, 2014, 427, 100-106.	1.1	37
152	Promoting clinical and laboratory interaction by harmonization. Clinica Chimica Acta, 2014, 432, 15-21.	1.1	56
153	Harmonization of laboratory testing â€" Current achievements and future strategies. Clinica Chimica Acta, 2014, 432, 4-7.	1.1	53
154	Tracing a roadmap for vitamin B12 testing using the health technology assessment approach. Clinical Chemistry and Laboratory Medicine, 2014, 52, 767-77.	2.3	8
155	â€œHarmonization of laboratory testing â€" A global activityâ€• Clinica Chimica Acta, 2014, 432, 1-3.	1.1	14
156	Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase. Clinical Biochemistry, 2013, 46, 148-151.	1.9	41
157	Avoid capture of interfering molecules in cardiac troponin immunoassays: Working in shifts. Clinical Biochemistry, 2013, 46, 961-962.	1.9	2
158	Standardization and analytical goals for glycated hemoglobin measurement. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1719-26.	2.3	30
159	Biological variation of free light chains in serum. Clinica Chimica Acta, 2013, 415, 10-11.	1.1	17
160	Biologic variation of copper, ceruloplasmin and copper/ceruloplasmin ratio (Cu:Cp) in serum. Clinica Chimica Acta, 2013, 415, 295-296.	1.1	8
161	Serum albumin: Accuracy and clinical use. Clinica Chimica Acta, 2013, 419, 15-18.	1.1	58
162	Estimate of intraindividual variability of C-reactive protein: A challenging issue. Clinica Chimica Acta, 2013, 419, 85-86.	1.1	10

#	Article	IF	Citations
163	Multi-marker network in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: When and what to measure. Clinica Chimica Acta, 2013, 417, 1-7.	1.1	2
164	New insights in the pathophysiology of acute myocardial infarction detectable by a contemporary troponin assay. Clinical Biochemistry, 2013, 46, 999-1006.	1.9	6
165	Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. Journal of Clinical Pathology, 2013, 66, 273-281.	2.0	150
166	Defining the need for a dynamic multimarker approach. Heart, 2013, 99, 433.1-433.	2.9	1
167	Measurement of icteric index as approach to detect abnormal total bilirubin values. Journal of Clinical Pathology, 2013, 66, 1095-1097.	2.0	11
168	Gaps in the Traceability Chain of Human Growth Hormone Measurements. Clinical Chemistry, 2013, 59, 1074-1082.	3.2	18
169	The Asian project for collaborative derivation of reference intervals: (1) strategy and major results of standardized analytes. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1429-42.	2.3	56
170	Measurement imprecision of common urinary biochemical analytes on the Roche Cobas 6000 system. Clinical Chemistry and Laboratory Medicine, 2013, 51, e175-e177.	2.3	2
171	Standardization and analytical goals for glycated hemoglobin measurement. Clinical Chemistry and Laboratory Medicine, 2013, 51, 2064-2064.	2.3	14
172	Defining acceptable limits for the metrological traceability of specific measurands. Clinical Chemistry and Laboratory Medicine, 2013, 51, 973-9.	2.3	37
173	The prognostic value of plasma fibrinogen concentrations of patients with ST-elevation myocardial infarction and treated by primary percutaneous coronary intervention: A cautionary message. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 355-362.	1.2	4
174	Implementation of new recommendations for the diagnosis of gestational diabetes: a 5-month audit. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1271-3.	2.3	1
175	Fatal Electrolyte Abnormalities Following Enema Administration. Clinical Chemistry, 2012, 58, 1515-1518.	3.2	8
176	Obtaining reference intervals traceable to reference measurement systems: is it possible, who is responsible, what is the strategy?. Clinical Chemistry and Laboratory Medicine, 2012, 50, 813-7.	2.3	34
177	The never-ending search of an acceptable compromise for pancreatic lipase standardisation. Clinical Chemistry and Laboratory Medicine, 2012, 50, 419-21.	2.3	10
178	Revaluating serum ferritin as a marker of body iron stores in the traceability era. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1911-1916.	2.3	41
179	Implementation of standardization in clinical practice: not always an easy task. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1237-1241.	2.3	71
180	Cardiac troponin: a critical review of the case for point-of-care testing in the ED. American Journal of Emergency Medicine, 2012, 30, 1639-1649.	1.6	74

#	Article	IF	Citations
181	Commutability of two JCTLM-listed secondary reference materials for two commercial lithium assays. Clinica Chimica Acta, 2012, 414, 152-153.	1.1	4
182	Comparative study of a new quantitative rapid test with an established ELISA method for faecal calprotectin. Clinica Chimica Acta, 2012, 413, 350-351.	1.1	17
183	Hemoglobin, bilirubin, and lipid interference on Roche Cobas 6000 assays. Clinica Chimica Acta, 2012, 413, 339-341.	1.1	12
184	Inside ST-elevation myocardial infarction by monitoring concentrations of cardiovascular risk biomarkers in blood. Clinica Chimica Acta, 2012, 413, 888-893.	1.1	16
185	Biologic variability of C-reactive protein: Is the available information reliable?. Clinica Chimica Acta, 2012, 413, 1179-1183.	1.1	36
186	Diagnostic value of transferrin. Clinica Chimica Acta, 2012, 413, 1184-1189.	1.1	58
187	Soluble Transferrin Receptor (sTfR) and sTfR/log Ferritin Index for the Diagnosis of Iron-Deficiency Anemia A Meta-Analysis. American Journal of Clinical Pathology, 2012, 138, 642-649.	0.7	103
188	Enzyme and Rate Analyses. , 2012, , 355-377.		1
189	Serum Enzymes. , 2012, , 565-598.		7
190	IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 Â°C. Part 9: Reference procedure for the measurement of catalytic concentration of alkaline phosphatase. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1439-46.	2.3	101
191	Is the accuracy of serum albumin measurements suitable for clinical application of the test?. Clinica Chimica Acta, 2011, 412, 791-792.	1.1	20
192	Revaluation of biological variation of glycated hemoglobin (HbA1c) using an accurately designed protocol and an assay traceable to the IFCC reference system. Clinica Chimica Acta, 2011, 412, 1412-1416.	1.1	46
193	Target organ damage in a population at intermediate cardiovascular risk, with adjunctive major risk factors: CArdiovascular PREvention Sacco Study (CAPRESS). Internal and Emergency Medicine, 2011, 6, 337-347.	2.0	2
194	The Analytical Goals for Hemoglobin A1c Measurement in IFCC Units and National Glycohemoglobin Standardization Program Units Are Different. Clinical Chemistry, 2011, 57, 1204-1206.	3.2	75
195	Focusing on the clinical impact of standardization of creatinine measurements: a report by the EFCC Working Group on Creatinine Standardization. Clinical Chemistry and Laboratory Medicine, 2011, 49, 977-82.	2.3	43
196	Commutability of the ERM-DA470k Reference Material for two assays measuring serum albumin using immunochemical principles. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1383-1384.	2.3	8
197	Impact of Implementation of the High-Sensitivity Cardiac Troponin T Assay in a University Hospital Setting. Clinical Chemistry, 2011, 57, 1211-1212.	3.2	11
198	Standardization of ceruloplasmin measurements is still an issue despite the availability of a common reference material. Analytical and Bioanalytical Chemistry, 2010, 397, 521-525.	3.7	19

#	Article	IF	Citations
199	IFCC Scientific Division. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1529-30.	2.3	2
200	Traceability of values for catalytic activity concentration of enzymes: a Certified Reference Material for aspartate transaminase. Clinical Chemistry and Laboratory Medicine, 2010, 48, 795-803.	2.3	3
201	Development of a candidate secondary reference procedure (immunoassay based measurement) Tj ETQq1 1 0.784314 rgBT /Overlock preliminary validation. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1603-10.	2.3	11
202	Application of traceability concepts to analytical quality control may reconcile total error with uncertainty of measurement. Clinical Chemistry and Laboratory Medicine, 2010, 48, 7-10.	2.3	65
203	Standardization in clinical enzymology: a challenge for the theory of metrological traceability. Clinical Chemistry and Laboratory Medicine, 2010, 48, 301-307.	2.3	35
204	Imprecision of tumour biomarker measurements on Roche Modular E170 platform fulfills desirable goals derived from biological variation. Annals of Clinical Biochemistry, 2010, 47, 171-173.	1.6	9
205	Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and Î³-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1593-1601.	2.3	90
206	Biological variability of glycated hemoglobin. Clinica Chimica Acta, 2010, 411, 1606-1610.	1.1	47
207	Standardisation of cardiac troponin I measurement: past and present. Pathology, 2010, 42, 402-408.	0.6	68
208	Foreword. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 3-3.	1.2	1
209	Cardiac: Is this biomarker ready for the prime time?. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 66-72.	1.2	7
210	Reference intervals: the way forward. Annals of Clinical Biochemistry, 2009, 46, 8-17.	1.6	147
211	A critical appraisal of experimental factors influencing the definition of the 99th percentile limit for cardiac troponins. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1179-82.	2.3	22
212	Traceability as a unique tool to improve standardization in laboratory medicine. Clinical Biochemistry, 2009, 42, 236-240.	1.9	76
213	Assay-related issues in the measurement of cardiac troponins. Clinica Chimica Acta, 2009, 402, 88-93.	1.1	66
214	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure. Clinical Biochemistry, 2008, 41, 222-226.	1.9	24
215	Prevalence of Pancreatic Insufficiency in Inflammatory Bowel Diseases. Assessment by Fecal Elastase-1. Digestive Diseases and Sciences, 2008, 53, 262-270.	2.3	51
216	Enzymatic assays for creatinine: Time for action. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 84-88.	1.2	44

#	Article	IF	Citations
217	Trueness verification of actual creatinine assays in the European market demonstrates a disappointing variability that needs substantial improvement. An international study in the framework of the EC4 creatinine standardization working group. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1319-25.	2.3	46
218	Final considerations. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 109-109.	1.2	0
219	Enzymatic assays for creatinine: time for action. Clinical Chemistry and Laboratory Medicine, 2008, 46, 567-72.	2.3	81
220	What's in a name? Standardisation of HbA1c: a response. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1326-7.	2.3	4
221	Biochemical Markers for Prediction of Chemotherapy-Induced Cardiotoxicity. American Journal of Clinical Pathology, 2008, 130, 688-695.	0.7	170
222	Standardization of troponin I measurements: an update. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1501-6.	2.3	47
223	Reference Intervals for Serum Creatinine Concentrations: Assessment of Available Data for Global Application. Clinical Chemistry, 2008, 54, 559-566.	3.2	197
224	Foreword. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 5-5.	1.2	0
225	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes. Clinical Chemistry, 2007, 53, 547-551.	3.2	188
226	Implementation of haemoglobin A1c results traceable to the IFCC reference system: the way forward. Clinical Chemistry and Laboratory Medicine, 2007, 45, 942-4.	2.3	33
227	Serum folate concentrations in patients with cortical and subcortical dementias. Neuroscience Letters, 2007, 420, 213-216.	2.1	11
228	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure. Circulation, 2007, 116, e95-8.	1.6	79
229	Traceability, reference systems and result comparability. Clinical Biochemist Reviews, 2007, 28, 97-104.	3.3	64
230	Standardisation--the theory and the practice. Clinical Biochemist Reviews, 2007, 28, 127-30.	3.3	7
231	Traceability in clinical enzymology. Clinical Biochemist Reviews, 2007, 28, 155-61.	3.3	12
232	The importance of metrological traceability on the validity of creatinine measurement as an index of renal function: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Clinical Chemistry and Laboratory Medicine, 2006, 44, 1287-92.	2.3	47
233	Trueness verification and traceability assessment of results from commercial systems for measurement of six enzyme activities in serum. Clinica Chimica Acta, 2006, 368, 160-167.	1.1	35
234	The new definition of myocardial infarction and the impact of troponin determination on clinical practice. International Journal of Cardiology, 2006, 106, 298-306.	1.7	37

#	Article	IF	Citations
235	Redefining reference limits needs more attention to the analytical aspects. Liver International, 2006, 26, 1155-1156.	3.9	3
236	Toward Standardization of Cardiac Troponin I Measurements Part II: Assessing Commutability of Candidate Reference Materials and Harmonization of Cardiac Troponin I Assays. Clinical Chemistry, 2006, 52, 1685-1692.	3.2	84
237	10% CV concentration for the fourth generation Roche cardiac troponin T assay derived from Internal Quality Control data. Clinical Chemistry and Laboratory Medicine, 2006, 44, 1495-6.	2.3	18
238	Pretreatment of Serum with Penicillamine: Effects on Capillary Electrophoresis Patterns and on Immunonephelometric Measurement of Immunoglobulins. Clinical Chemistry, 2006, 52, 772-774.	3.2	1
239	Cardiac Natriuretic Hormones as Markers of Cardiovascular Disease: Methodological Aspects. , 2006, , 65-89.		5
240	The importance of analytical quality specifications for biomarker assays currently used in acute cardiac care. Acute Cardiac Care, 2006, 8, 133-138.	0.2	6
241	Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program. Clinical Chemistry, 2006, 52, 5-18.	3.2	1,057
242	National survey on the use of measurement of cholinesterase activity in serum. Clinical Chemistry and Laboratory Medicine, 2005, 43, 256-7.	2.3	0
243	Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. Clinical Chemistry, 2005, 51, 810-824.	3.2	385
244	Quality Specifications for B-Type Natriuretic Peptide Assays. Clinical Chemistry, 2005, 51, 486-493.	3.2	181
245	Standardization of Cardiac Troponin I Measurements: The Way Forward?. Clinical Chemistry, 2005, 51, 1594-1597.	3.2	34
246	Measurement of troponin I 48h after admission as a tool to rule out impaired left ventricular function in patients with a first myocardial infarction. Clinical Chemistry and Laboratory Medicine, 2005, 43, 848-54.	2.3	20
247	Selection of Antibodies and Epitopes for Cardiac Troponin Immunoassays: Should We Revise Our Evidence-Based Beliefs?. Clinical Chemistry, 2005, 51, 803-804.	3.2	24
248	Innotrac Aio! Second-Generation Cardiac Troponin I Assay: Imprecision Profile and Other Key Characteristics for Clinical Use. Clinical Chemistry, 2004, 50, 1271-1272.	3.2	13
249	The Interfering Component in Cardiac Troponin I Immunoassays: Need for Further Experimental Evidence. Clinical Chemistry, 2004, 50, 676-677.	3.2	6
250	Multicenter Evaluation of the TOSOH AIA-Pack Second-Generation Cardiac Troponin I Assay. Clinical Chemistry, 2004, 50, 1707-1709.	3.2	8
251	AACC Creatine Kinase MB (CK-MB) Standardization Material Used as Manufacturerâ€™s Working Calibrator Is Unable to Harmonize CK-MB Results between Two Commercial Immunoassays. Clinical Chemistry, 2004, 50, 1711-1712.	3.2	9
252	Current concepts in standardization of cardiac marker immunoassays. Clinical Chemistry and Laboratory Medicine, 2004, 42, 3-8.	2.3	20

#	Article	IF	Citations
253	External Quality Assessment for biochemical markers of myocardial damage: an Italian experience. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1434-41.	2.3	6
254	Evaluation of Imprecision for Cardiac Troponin Assays at Low-Range Concentrations. Clinical Chemistry, 2004, 50, 327-332.	3.2	342
255	Multicenter evaluation of analytical performance of the LiaisonÂ® troponin I assay. Clinical Biochemistry, 2004, 37, 750-757.	1.9	16
256	Role and importance of biochemical markers in clinical cardiology. European Heart Journal, 2004, 25, 1187-1196.	2.2	118
257	Standardization of immunoassays for measurement of myoglobin in serum. Phase I: Evaluation of candidate secondary reference materials. Clinica Chimica Acta, 2004, 341, 65-72.	1.1	20
258	Biochemical markers of cardiac diseases. Journal of Medical Biochemistry, 2004, 23, 201-211.	0.1	10
259	The future of laboratory medicine: understanding the new pressures. Clinical Biochemist Reviews, 2004, 25, 207-15.	3.3	43
260	Assay Using Succinyldithiocholine as Substrate: The Method of Choice for the Measurement of Cholinesterase Catalytic Activity in Serum to Diagnose Succinyldicholine Sensitivity. Clinical Chemistry and Laboratory Medicine, 2003, 41, 317-22.	2.3	8
261	Rapid Determination of Brain Natriuretic Peptide in Patients with Acute Myocardial Infarction. Clinical Chemistry and Laboratory Medicine, 2003, 41, 164-8.	2.3	21
262	On the Comparison of Serum and Plasma Samples in Troponin Assays. Clinical Chemistry, 2003, 49, 835-a-836.	3.2	4
263	Reference Interval for Lactate Dehydrogenase Catalytic Activity in Serum Measured According to the New IFCC Recommendations. Clinical Chemistry and Laboratory Medicine, 2003, 41, 970-1.	2.3	10
264	Frequency of butyrylcholinesterase gene mutations in individuals with abnormal inhibition numbers. Pharmacogenetics and Genomics, 2003, 13, 265-270.	5.7	50
265	Standardization of Cardiac Markers. , 2003, , 213-229.		1
266	Recommendations on Use of Biochemical Markers in Acute Coronary Syndrome: IFCC Proposals. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2003, 14, 104-108.	0.7	1
267	IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37Â°C. Part 2. Reference Procedure for the Measurement of Catalytic Concentration of Creatine Kinase. Clinical Chemistry and Laboratory Medicine, 2002, 40, 635-42.	2.3	104
268	IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37C. Part 6. Reference Procedure for the Measurement of Catalytic Concentration of Î³-Glutamyltransferase. Clinical Chemistry and Laboratory Medicine, 2002, 40, 734-8.	2.3	100
269	IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37Â°C. Part 5. Reference Procedure for the Measurement of Catalytic Concentration of Aspartate Aminotransferase. Clinical Chemistry and Laboratory Medicine, 2002, 40, 725-33.	2.3	145
270	IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37Â°C. Part 4. Reference Procedure for the Measurement of Catalytic Concentration of Alanine Aminotransferase. Clinical Chemistry and Laboratory Medicine, 2002, 40, 718-24.	2.3	210

#	Article	IF	Citations
271	IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37Â°C. Part 3. Reference Procedure for the Measurement of Catalytic Concentration of Lactate Dehydrogenase. Clinical Chemistry and Laboratory Medicine, 2002, 40, 643-8.	2.3	80
272	Recommendations for the Routine Use of Pancreatic Amylase Measurement instead of Total Amylase for the Diagnosis and Monitoring of Pancreatic Pathology. Clinical Chemistry and Laboratory Medicine, 2002, 40, 97-100.	2.3	24
273	The Measurement of Cardiac Markers. American Journal of Clinical Pathology, 2002, 118, 354-361.	0.7	31
274	Acute Coronary Syndrome. Chest, 2002, 122, 1428-1435.	0.8	64
275	IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37Â°C. Part 7. Certification of Four Reference Materials for the Determination of Enzymatic Activity of Î³-Glutamyltransferase, Lactate Dehydrogenase, Alanine Aminotransferase and Creatine Kinase according to IFCC Reference Procedures at 37Â°C. Clinical Chemistry and Laboratory Medicine, 2002, 40, 739-45.	2.3	46
276	Evaluation of a sandwich enzyme-linked immunosorbent assay for the measurement of serum heart fatty acid-binding protein. Annals of Clinical Biochemistry, 2002, 39, 404-405.	1.6	27
277	IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37Â°C. Part 1. The Concept of Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes. Clinical Chemistry and Laboratory Medicine, 2002, 40, 631-4.	2.3	43
278	Single-Point Cardiac Troponin T at Coronary Care Unit Discharge after Myocardial Infarction Correlates with Infarct Size and Ejection Fraction. Clinical Chemistry, 2002, 48, 1432-1436.	3.2	89
279	Performance of Todayâ€™s Cardiac Troponin Assays and Tomorrowâ€™s. Clinical Chemistry, 2002, 48, 809-810.	3.2	37
280	Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. Clinical Chemistry, 2002, 48, 1432-6.	3.2	30
281	Recent approaches in standardization of cardiac markers. Clinica Chimica Acta, 2001, 311, 19-25.	1.1	17
282	Standardization of Cardiac Troponin I Assays: Round Robin of Ten Candidate Reference Materials. Clinical Chemistry, 2001, 47, 431-437.	3.2	106
283	Biological Variation in Serum Activities of Three Hepatic Enzymes. Clinical Chemistry, 2001, 47, 355-356.	3.2	10
284	Comparative study of cardiac troponin I and T measurements in a routine extra-cardiological clinical setting. Journal of Clinical Laboratory Analysis, 2001, 15, 210-214.	2.1	12
285	Establishing a Reference System in Clinical Enzymology. Clinical Chemistry and Laboratory Medicine, 2001, 39, 795-800.	2.3	48
286	Quality Specifications for Cardiac Troponin Assays. Clinical Chemistry and Laboratory Medicine, 2001, 39, 175-9.	2.3	124
287	Evaluation of a Rapid Bedside Immunochromatographic Assay for Detection of Cardiac Troponin I in Whole Blood. Clinical Chemistry and Laboratory Medicine, 2001, 39, 458-9.	2.3	6
288	Certification of the Mass Concentration of Creatine Kinase Isoenzyme 2 (CK-MB) in the Reference Material BCR 608. Clinical Chemistry and Laboratory Medicine, 2001, 39, 858-65.	2.3	5

#	Article	IF	Citations
289	Present issues in the determination of troponins and other markers of cardiac damage. Clinical Biochemistry, 2000, 33, 161-166.	1.9	32
290	Multicenter Evaluation of Five Assays for Myoglobin Determination. Clinical Chemistry, 2000, 46, 1631-1637.	3.2	18
291	Serum and Plasma Samples for ACS:Systems Cardiac Markers. Clinical Chemistry, 2000, 46, 1020-1022.	3.2	16
292	Biological Variation in Serum Type I Collagen Carboxy-Terminal Telopeptide Concentrations. Clinical Chemistry, 2000, 46, 1439-1440.	3.2	1
293	Evaluation of a Fully Automated Assay to Measure C-Telopeptide of Type I Collagen in Serum. Clinical Chemistry and Laboratory Medicine, 2000, 38, 1111-1113.	2.3	18
294	Determination of Decision Limits for ACS:Systems Cardiac Troponin I. Clinical Chemistry and Laboratory Medicine, 2000, 38, 1155-7.	2.3	10
295	The Sensitivity of Cardiac Markers: an Evidence-based Approach. Clinical Chemistry and Laboratory Medicine, 1999, 37, 1097-106.	2.3	59
296	Use of Biochemical Markers in Acute Coronary Syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. Clinical Chemistry and Laboratory Medicine, 1999, 37, 687-93.	2.3	104
297	Cardiac troponin elevations in chronic renal failure: prevalence and clinical significance. Clinical Biochemistry, 1999, 32, 125-130.	1.9	82
298	Clinical and analytical performance of automated immunochemiluminometric assays for determination of cardiac markers in serum. , 1998, 13, 307-309.		6
299	Diagnostic application of CK-MB mass determination. Clinica Chimica Acta, 1998, 272, 23-31.	1.1	26
300	IFCC Committee on Standardization of Markers of Cardiac Damage: Premises and Project Presentation. Clinical Chemistry and Laboratory Medicine, 1998, 36, 887-93.	2.3	16
301	Myosin Light and Heavy Chains. , 1998, , 245-256.		0
302	Biological Variation of Myoglobin in Serum. Clinical Chemistry, 1997, 43, 2435-2435.	3.2	43
303	Rapid, Highly Sensitive Immunoassay for Determination of Cardiac Troponin I in Patientswith Myocardial Cell Damage. Clinical Chemistry, 1997, 43, 1464-1465.	3.2	22
304	Enzyme and muscle diseases. Current Opinion in Rheumatology, 1995, 7, 469-474.	4.3	17
305	Nonenzymic glycation of apolipoprotein B in patients with insulin- and noninsulin-dependent diabetes mellitus. Clinical Biochemistry, 1995, 28, 587-592.	1.9	8
306	Significance of various parameters derived from biological variability for lipid and lipoprotein analyses. Clinical Biochemistry, 1993, 26, 415-420.	1.9	14

#	Article	IF	Citations
307	Diagnostic value of four assays for lipase determination in serum: A comparative reevaluation. Clinical Biochemistry, 1991, 24, 497-503.	1.9	10
308	An immunochemical procedure for determination of creatine kinase 31 (serum-specific) isoform in human serum evaluated. Clinical Biochemistry, 1990, 23, 225-228.	1.9	7
309	Diagnostic value of measuring pancreatic isoamylase with a doubleâ€“monoclonal antibody immunoassay in serum of hospitalized hyperamylasemic patients. Journal of Clinical Laboratory Analysis, 1990, 4, 449-452.	2.1	8
310	Aspartate aminotransferase isoenzymes. Clinical Biochemistry, 1990, 23, 311-319.	1.9	85
311	Time course of changes in serum activity of the P3 isoform of pancreatic amylase isoenzyme in patients with acute pancreatitis. Clinical Biochemistry, 1989, 22, 479-482.	1.9	4
312	Methods for serum cholinesterase assay and classification of genetic variants. Clinica Chimica Acta, 1989, 183, 87-90.	1.1	4
313	Serum isoforms of creatine kinase isoenzymes. Clinical Biochemistry, 1988, 21, 211-218.	1.9	44
314	Serum isoforms of creatine kinase MM and MB in myocardial infarction. An appraisal of quantitative, clinical and pathophysiological information. Scandinavian Journal of Clinical and Laboratory Investigation, 1987, 47, 325-329.	1.2	11
315	Isoforms of creatine kinase MM and MB in acute myocardial infarction: a clinical evaluation. Clinica Chimica Acta, 1986, 155, 1-9.	1.1	32
316	Evaluation of a new method for cholinesterase determination. Clinical Biochemistry, 1986, 19, 161-165.	1.9	9
317	Serum enzymes in acute myocardial infarction after intracoronary thrombolysis. Clinical Biochemistry, 1986, 19, 294-297.	1.9	16
318	Evaluation of the direct potentiometric method for serum chloride determinationâ€”comparison with the most commonly employed methodologies. Clinical Biochemistry, 1986, 19, 20-25.	1.9	8
319	A simple method for quantitative determination of lipoprotein-X (LP-X) in human serum. Clinica Chimica Acta, 1985, 151, 187-192.	1.1	3
320	A single reagent method for determination of total and conjugated bilirubin with a centrifugal analyser. Clinica Chimica Acta, 1983, 128, 407-414.	1.1	1